CION Ameerpet
Duration, Stopping & Restarting
Adjuvant immunotherapy — why is it exactly one year?
Adjuvant immunotherapy is given after surgery, when scans show no cancer left. That single fact is why its length works differently from immunotherapy for advanced disease — there is nothing on a scan to steer the decision. The twelve-month course you have been told about is simply the length the adjuvant trials behind NCCN, ASCO and ESMO guidance actually tested. This page explains why one year, whether it can be shorter, and what happens if side effects arrive at month nine.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Where one year comes from — the adjuvant trials tested a fixed twelve-month course, so that is the length with evidence behind it
- A different question from advanced disease — with no visible cancer, there is no scan response to lengthen or shorten your course
- It can be shortened — what your oncologist weighs when side effects, cost or travel make twelve months unrealistic
- Month nine is not too late to speak up — how a hold, a restart or an early finish is decided, and why nine months is not wasted
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Start Here
Why is adjuvant immunotherapy given for exactly one year?
Because one year is the course that was actually tested. The adjuvant trials that led to approval treated patients for about twelve months after surgery and then measured what happened. No trial has shown a longer course does better. So NCCN, ASCO and ESMO guidance describes adjuvant immunotherapy as a fixed course of roughly one year.
That is the whole explanation. There is no biological switch that flips at twelve months. There is a period that was studied, and a period that was not. Your oncologist follows the tested one because that is where the evidence sits.
It also means the number is allowed to move for a specific patient with a specific reason. A fixed course is a starting plan, not a contract. What it is not is something you should change quietly on your own.
Did you know?
Adjuvant duration and metastatic duration are two different questions wearing the same word. After surgery there is no visible cancer on the scan, so nothing can be measured shrinking. Duration therefore comes from the trial protocol, not from your response. Most pages that answer "how long is immunotherapy" are quietly answering the other question.
The Distinction That Matters
Why is duration after surgery a different question from duration for advanced cancer?
In advanced disease, scans measure the cancer, so the response can steer how long treatment runs. After surgery there is nothing visible to measure. Duration therefore comes from the protocol, not from your imaging. That single difference explains most of the confusion patients meet online.
| What changes | After surgery (adjuvant) | Cancer visible on scans (advanced) |
|---|---|---|
| What imaging shows at the start | Nothing measurable. Surgery has removed the visible disease. | Measurable disease that can be tracked cycle to cycle. |
| What sets the length | A pre-set course carried over from the trials. | Response on scans, weighed against side effects. |
| Usual planned length | About twelve months. | Often longer, and sometimes continued while it keeps working. |
| How you know it is working | You cannot see it working. That is the genuinely hard part. | Shrinkage or stability on the next response scan. |
| Why treatment stops | The planned course finishes, or side effects force a change. | Response, side effects, or the cancer progressing. |
| What a scan is for | Checking the cancer has not come back. | Measuring how the cancer is responding right now. |
Response assessment imaging for CION patients is coordinated at partner imaging centres. Immunotherapy itself is given as day care at CION centres.
Can It Be Shorter?
Can the one year be made shorter?
Sometimes, yes, but it is a clinician-led decision. A shorter course is not a standard plan. It is what happens when side effects, another illness, or cost make twelve months unrealistic. Your oncologist weighs those against the fact that a shorter course has less evidence behind it. These are the things actually on the table.
Months completed
How far into the course you already are
Ten months completed and two remaining is a different conversation from two months completed and ten remaining.
Side-effect burden
What the treatment has cost you so far
A significant immune-related reaction is a clinical reason to stop early, and it outranks finishing the calendar.
Other health conditions
What else your body is managing
An autoimmune condition, a new infection, or another organ problem can change the balance mid-course.
Cost and travel
What twelve months means for your family
Repeated cycles carry repeated cost and repeated travel. Say it out loud. It belongs in the medical conversation.
Not continuing
Stopping is a real option, not a failure
Choosing to stop, or to decline adjuvant treatment from the start, is a described path with its own follow-up plan.
Tumour board
More than one specialist reviews it
A change to a planned course is reviewed by the team at CION, not decided in a corridor by one person.
None of this predicts your own outcome. Completing twelve months does not mean the cancer will definitely stay away, and finishing at nine does not mean it will return. Anyone offering you a number on that is overreaching.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer on your own twelve months
Bring your surgery notes and treatment dates. We will walk through where you are in the course and what your options actually are.
Month Nine
What if side effects appear at month nine?
Tell your oncology team the same day. Do not wait for the next cycle. Most immune-related side effects are handled first by holding treatment, not by abandoning it. Whether you restart or finish early is decided after the team grades the reaction. Nine months of a planned twelve is not wasted treatment.
Do not manage these at home. Chest pain, new or worsening breathlessness, heavy or bloody diarrhoea, severe abdominal pain, confusion, or collapse need emergency assessment now. Go to the nearest emergency department, and tell them you are on immunotherapy. For anything less urgent, call the CION helpline the same day: 1800 202 8726.
Late-appearing reactions are not unusual. Immune-related side effects can begin at any point in a course and, in some patients, weeks or months after the final dose. Month nine is not too late for a reaction and it is not too late to report one.
What patients most often fear at that point is that speaking up will get their treatment cancelled. Holding a cycle is the common first step, not cancellation. Staying quiet to protect the schedule is the option that actually causes harm.
How The Call Gets Made
How does a team decide between holding, restarting and finishing early?
Stopping an adjuvant course early is a clinician-led decision with a defined path. It is not a judgement call made in the infusion chair. This is the sequence most CION patients go through.
1
You report the symptom the same day
Timing matters more than detail. A phone call describing a new symptom is enough to start the process, even if you are unsure it is related.
2
The reaction is assessed and graded
Your team examines you and orders the tests that fit the symptom. Severity is graded using the standard scales that NCCN and ASCO toxicity guidance is built on.
3
Treatment is usually held, not cancelled
For many reactions the next cycle is postponed while the problem is treated. A hold is a pause with a review date attached, not a decision to stop.
4
Restart or complete early is decided together
The team weighs how the reaction settled, how many months you have completed, and your own priorities on cost and quality of life. Both options are explained before you choose.
5
A follow-up schedule is set either way
Whether you finish the twelve months or stop at nine, scans and clinic reviews continue on an agreed schedule so any change is picked up early.
If You Finish Early
Is finishing early the same as the treatment having failed?
No. Adjuvant immunotherapy is intended to lower the chance of the cancer returning in someone who has no visible disease today. It is not treating something that can be seen shrinking, so an early finish cannot be scored as a failure the way a progressing scan can. What changes is the amount of the tested course you received.
Be careful with certainty in either direction. Completing all twelve months does not mean the cancer will definitely stay away. Finishing at nine does not mean it will come back. Your oncologist can describe how your own case is viewed, and that is a more useful conversation than a number from a page like this one.
Declining adjuvant treatment altogether is also a described option, and a reasonable one to raise. If you are weighing it, ask what the follow-up plan would look like without treatment. Then you are choosing between two paths that have both been explained, rather than between one path and a blank.
Cost and treatment fatigue belong in that discussion too. Twelve months of cycles is a long commitment for any family, and CION discusses cost openly rather than leaving it to the billing desk. Any figure quoted to you is indicative only, as of August 2026, and depends on your regimen and centre.
Related Reading
Where to read next on treatment length
- How Long Do You Stay on Immunotherapy? — the wider picture, including the settings where duration is steered by response rather than by a fixed course.
- Can You Stay on Immunotherapy Beyond Two Years? — the opposite question, and why it belongs to advanced disease rather than the adjuvant setting.
- What Happens to Your Immune System After Stopping? — useful once your twelve months finish, including why late reactions can still appear.
- Immunotherapy at CION Cancer Clinics — how immunotherapy is delivered as day care across our centres, and what to expect at a first consultation.
This page is general information and does not replace a consultation. It describes how adjuvant treatment duration is generally planned, drawn from published guideline and patient-education material from bodies including NCCN, ASCO and ESMO. It is not a prediction for any individual patient. Decisions to continue, shorten, pause or stop adjuvant immunotherapy are made by your treating oncologist together with you, based on your own case. Any cost referred to is indicative only, as of August 2026.
You are not the only one asking
Wanting to know why it is a year is a fair question
Twelve months of cycles is a long commitment when you feel well and cannot see the treatment working. Our team explains the reasoning in plain language, in a 45-minute consultation.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Adjuvant immunotherapy duration: your questions answered
Why is adjuvant immunotherapy given for exactly one year?
Because one year is the course that was actually tested. The adjuvant trials that led to approval treated patients for about twelve months after surgery and then measured what happened. No trial has shown that a longer course does better, and no trial has shown that a shorter one does the same. So NCCN, ASCO and ESMO guidance describes adjuvant immunotherapy as a fixed course of roughly one year rather than an open-ended treatment. The number is a tested duration, not a biological deadline, and your oncologist may adjust it for your own case.
Can adjuvant immunotherapy be shorter than one year?
Sometimes, yes, but it is a clinician-led decision rather than one you make on your own. A shorter course is not a standard plan. It is what happens when side effects, another illness, or the real cost and travel burden make twelve months unrealistic for a particular patient. Your oncologist weighs those pressures against the fact that a shorter course carries less evidence behind it. If cost or fatigue is the reason, say so plainly at your next visit. It is a legitimate part of the conversation, not a complaint to keep quiet about.
What if side effects appear at month nine?
Tell your oncology team the same day. Do not wait for the next cycle and do not manage it at home. Most immune-related side effects are handled first by holding treatment, not by abandoning it, and many patients restart once the reaction settles. Whether you restart or finish early is decided after the team grades the reaction and reviews how many months you have already completed. Nine months of a planned twelve is not wasted treatment. For chest pain, severe breathlessness, heavy diarrhoea, confusion or collapse, go to the nearest emergency department now.
Is adjuvant immunotherapy duration a different question from immunotherapy for advanced cancer?
Yes, and this is the part most pages blur. In advanced disease there is measurable cancer on a scan, so response can steer how long treatment continues. After surgery there is nothing visible to measure, so a scan cannot tell your oncologist that the drug is working. That is precisely why the adjuvant course is a pre-set length taken from the trials instead of a response-led one. Comparing your twelve months to someone else's two years on immunotherapy for advanced disease compares two different situations.
Can I choose not to have adjuvant immunotherapy at all?
Yes. Declining adjuvant treatment, or asking for time to think, is a real option and a reasonable one to raise. Adjuvant immunotherapy is offered to lower the chance of the cancer returning in people who currently have no visible disease. It is not treating something you can see, so the balance between possible benefit and possible side effects is genuinely a shared decision. Ask your oncologist what the plan would be if you declined, including the follow-up schedule, so you are choosing between two described paths rather than one.
What happens after the twelve months finish?
Treatment stops and monitoring begins. You move to a follow-up schedule of clinic reviews and scans agreed with your team, which is designed to pick up any change early. Finishing the course is not the same as being discharged from cancer care. Some immune-related side effects can also appear weeks or months after the last dose, so keep telling any doctor you see that you had immunotherapy, even after treatment ends. Your oncologist will tell you how long that matters for in your own case.